1. Design, synthesis, and biological evaluation of new cinnamic derivatives as antituberculosis agents.
- Author
-
De P, Koumba Yoya G, Constant P, Bedos-Belval F, Duran H, Saffon N, Daffé M, and Baltas M
- Subjects
- Amides chemical synthesis, Amides chemistry, Amides pharmacology, Antitubercular Agents chemistry, Antitubercular Agents pharmacology, Cinnamates chemistry, Cinnamates pharmacology, Crystallography, X-Ray, Drug Design, Drug Resistance, Bacterial, Hydrazines chemical synthesis, Hydrazines chemistry, Hydrazines pharmacology, Isoniazid pharmacology, Microbial Sensitivity Tests, Molecular Structure, Mycobacterium tuberculosis chemistry, Mycobacterium tuberculosis drug effects, Mycolic Acids analysis, Phthalazines chemistry, Phthalazines pharmacology, Stereoisomerism, Structure-Activity Relationship, Triazoles chemistry, Triazoles pharmacology, Antitubercular Agents chemical synthesis, Cinnamates chemical synthesis, Phthalazines chemical synthesis, Triazoles chemical synthesis
- Abstract
Tuberculosis, HIV coinfection with TB, emergence of multidrug-resistant TB, and extensively drug-resistant TB are the major causes of death from infectious diseases worldwide. Because no new drug has been introduced in the last several decades, new classes of molecules as anti-TB drugs are urgently needed. Herein, we report the synthesis and structure-activity relationships of a series of thioester, amide, hydrazide, and triazolophthalazine derivatives of 4-alkoxy cinnamic acid. Many compounds exhibited submicromolar minimum inhibitory concentrations against Mycobacterium tuberculosis strain (H(37)Rv). Interestingly, compound 13e, a 4-isopentenyloxycinnamyl triazolophthalazine derivative, was found to be 100-1800 times more active than isoniazid (INH) when tested for its ability to inhibit the growth of INH-resistant M. tuberculosis strains. The results also revealed that 13e does not interfere with mycolic acid biosynthesis, thereby pointing to a different mode of action and representing an attractive lead compound for the development of new anti-TB agents.
- Published
- 2011
- Full Text
- View/download PDF